Type I interferons in anticancer immunity

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Virus interference. I. the interferon

Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Interferon-α inducible protein 6 (IFI6) confers protection against ionizing radiation in skin cells

Jia, H., Mo, W., Hong, M. H., Jiang, S., Zhang, Y., He, D., Yu, D., Shi, Y., Cao, J., Xu, X., et al. (2020) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2020.09.003 · Cited by 31

The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer

García‐Estévez, L., González-Martínez, S., & Moreno‐Bueno, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.784823 · Cited by 33

Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers

Atukorale, P. U., Moon, T. J., Bokatch, A. R., Lusi, C. F., Routhier, J. T., Deng, V. J., & Karathanasis, E. (2022) · Nanoscale · doi:10.1039/d1nr06577g · Cited by 32

Gospel of malignant Glioma: Oncolytic virus therapy

Li, J., Meng, Q., Zhou, X., Zhao, H., Wang, K., Niu, H., & Wang, Y. (2022) · Gene · doi:10.1016/j.gene.2022.146217 · Cited by 31

Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer

Plundrich, D., Chikhladze, S., Fichtner‐Feigl, S., Feuerstein, R., & Briquez, P. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052782 · Cited by 31

MnO 2 nanoparticles as a minimalist multimode vaccine adjuvant/delivery system to regulate antigen presenting cells for tumor immunotherapy

Song, T., Liao, Y., Zuo, Q., Liu, N., & Liu, Z. (2022) · Journal of Materials Chemistry B · doi:10.1039/d1tb02650j · Cited by 31

Therapeutic potential of autophagy in immunity and inflammation: current and future perspectives

Zuo, H., Chen, C., & Sa, Y. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00486-0 · Cited by 34

Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment

Singh, S., Barik, D., Arukha, A. P., Prasad, S., Mohapatra, I., Singh, A. R., & Singh, G. (2023) · Biomedicines · doi:10.3390/biomedicines11102621 · Cited by 31

Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents

Truxová, I., Hensler, M., Škapa, P., Halaška, M. J., Laco, J., Ryška, A., Spisek, R., & Fucikova, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.003 · Cited by 31

Targeting activation of cGAS-STING signaling pathway by engineered biomaterials for enhancing cancer immunotherapy

Liang, J., Jin, X., Deng, X., Huang, Q., Zhang, S., Chen, W., & Zhang, X. (2024) · Materials Today · doi:10.1016/j.mattod.2024.07.004 · Cited by 30

The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates

Kan, L., Yu, Y., Wang, Y., Shi, L., Fan, T., Chen, H., & Ren, C. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02328-4 · Cited by 32

Emerging nanotechnologies for cancer immunotherapy

Shukla, S., & Steinmetz, N. F. (2016) · Experimental Biology and Medicine · doi:10.1177/1535370216647123 · Cited by 32

Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance

Heß, J., Unger, K., Orth, M., Schötz, U., Schüttrumpf, L., Zangen, V., Gimenez-Aznar, I., Michna, A., Schneider, L., Stamp, R., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.014 · Cited by 30

SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile

Sun, J., Yi, S., Qiu, L., Fu, W., Wang, A., Liu, F., Wang, L., Wang, T., Chen, H., Wang, L., et al. (2018) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.02.028 · Cited by 30

Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response

Yin, P., Li, H., Ke, C., Cao, G., Xin, X., Hu, J., Cai, X., Li, L., Liu, X., & Du, B. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s240551 · Cited by 30

Tumor Milieu Controlled by RB Tumor Suppressor

Kitajima, S., Li, F., & Takahashi, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072450 · Cited by 30

Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation

Henrich, I. C., Jain, K., Young, R., Quick, L., Lindsay, J. M., Park, D. H., Oliveira, A. M., Blobel, G. A., & Chou, M. M. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1458 · Cited by 30

A Variety of Nucleic Acid Species Are Sensed by cGAS, Implications for Its Diverse Functions

Wang, D., Zhao, H., Shen, Y., & Chen, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.826880 · Cited by 34

Novel Mechanisms and Future Opportunities for the Management of Radiation Necrosis in Patients Treated for Brain Metastases in the Era of Immunotherapy

Vaios, E., Winter, S. F., Shih, H. A., Dietrich, J., Peters, K. B., Floyd, S., Kirkpatrick, J. P., & Reitman, Z. J. (2023) · Cancers · doi:10.3390/cancers15092432 · Cited by 31

IFN-γ: An overlooked cytokine in dermatomyositis with anti-MDA5 antibodies

Thuner, J., & Coutant, F. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103420 · Cited by 30

Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387

Wang, Y., Jing, N., Willard, B. B., Wang, X., Yang, J. B., & Stark, G. R. (2016) · The EMBO Journal · doi:10.15252/embj.201694834 · Cited by 30

ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate

Amôr, N. G., de Oliveira, C. E., Gasparoto, T. H., Boas, V. G. V., Perri, G., Kaneno, R., Lara, V. S., Garlet, G. P., Silva, J. S., Martins, G. A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25768 · Cited by 30

DNASE1L3 enhances antitumor immunity and suppresses tumor progression in colon cancer

Li, W., Nakano, H., Fan, W., Li, Y., Sil, P., Nakano, K., Zhao, F., Karmaus, P. W. F., Grimm, S. A., Shi, M. Y., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.168161 · Cited by 31

Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18

Miyauchi, S., Arimoto, K., Liu, M., Zhang, Y., & Zhang, D. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113560 · Cited by 29

Type I interferon regulation by USP18 is a key vulnerability in cancer

Jové, V., Wheeler, H., Lee, C. W., Healy, D. R., Levine, K. K., Ralph, E. C., Yamaguchi, M., Jiang, Z. K., Cabral, E., Xu, Y., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109593 · Cited by 30

Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer

Sandoval, T. A., Salvagno, C., Chae, C.-S., Awasthi, D., Giovanelli, P., Falco, M. M., Hwang, S., Terán-Cabanillas, E., Suominen, L., Yamazaki, T., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1451 · Cited by 29

Advances in Immunomodulatory Mesoporous Silica Nanoparticles for Inflammatory and Cancer Therapies

Gu, B., Zhao, Q. P., & Ao, Y. (2024) · Biomolecules · doi:10.3390/biom14091057 · Cited by 29

Implanted Microneedles Loaded with Sparfloxacin and Zinc‐Manganese Sulfide Nanoparticles Activates Immunity for Postoperative Triple‐Negative Breast Cancer to Prevent Recurrence and Metastasis

Chu, Z., Wang, Z., Fu, W., Liang, J., Wang, W., Xu, L., Jiang, X., Zha, Z., & Qian, H. (2025) · Advanced Science · doi:10.1002/advs.202416270 · Cited by 29

Bioengineering strategies to optimize STING agonist therapy

Dosta, P., Cryer, A. M., Prado, M., & Artzi, N. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00337-y · Cited by 31

Interferon-α Promotes the Expression of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma

Ma, H., Jin, S., Yang, W., Tian, Z., Liu, S., Wang, Y., Zhou, G., Zhao, M., Gvetadze, S. R., Zhang, Z., et al. (2017) · Journal of Cancer · doi:10.7150/jca.19486 · Cited by 30

Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals

Zhou, H., Mondragón, L., Xie, W., Mauseth, B., Leduc, M., Sauvat, A., Gomes-da-Silva, L. C., Forveille, S., Iribarren, K., Souquère, S., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1127-3 · Cited by 30

Evaluation of Newcastle disease virus mediated dendritic cell activation and cross‐priming tumor‐specific immune responses ex vivo

Xu, Q., Rangaswamy, U. S., Wang, W., Robbins, S. H., Harper, J. A., Jin, H., & Cheng, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32694 · Cited by 29

oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity

Zhang, W., Hu, X., Liang, J., Zhu, Y., Zeng, B., Feng, L., Zhao, C., Liu, S., Liu, B., & Zhang, K. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.12.012 · Cited by 29

MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis

Karimzadeh, M. R., Zarin, M., Ehtesham, N., Khosravi, S., Soosanabadi, M., Mosallaei, M., & Pourdavoud, P. (2020) · Cancer Gene Therapy · doi:10.1038/s41417-020-0172-0 · Cited by 29

Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl2 Inhibit Melanoma via Regulating Macrophage Polarization and Dendritic Cell Maturation

Liu, X., Xu, Y., Yin, L., Hou, Y., & Zhao, S. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s318363 · Cited by 29

Ghost mitochondria drive metastasis through adaptive GCN2/Akt therapeutic vulnerability

Ghosh, J. C., Perego, M., Agarwal, E., Bertolini, I., Wang, Y., Goldman, A. R., Tang, H., Kossenkov, A. V., Landis, C. J., Languino, L. R., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2115624119 · Cited by 29

The pleiotropic roles of cGAS–STING signaling in the tumor microenvironment

Li, J., & Bakhoum, S. F. W. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac019 · Cited by 30

Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246

Zhou, X., Sanz, G., Zhan, Y., Oliveira, M. M. S., Rezaei, S., Singh, M., Peuget, S., Westerberg, L. S., Johnsen, J. I., & Selivanova, G. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01971-8 · Cited by 31

Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer

Hargadon, K. M. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04689-9 · Cited by 30

MHC-dressing on dendritic cells: Boosting anti-tumor immunity via unconventional tumor antigen presentation

Chatterjee, F., & Spranger, S. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101710 · Cited by 31

Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1

Li, Y., Mahadevan, N. R., Duplaquet, L., Hong, D., Durmaz, Y. T., Jones, K. L., Cho, H., Morrow, M., Protti, A., Poitras, M. J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101282 · Cited by 30

DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells

Laengle, J., Stift, J., Bilecz, Á., Wolf, B., Beer, A., Hegedűs, B., Stremitzer, S., Starlinger, P. P., Tamandl, D., Pils, D., et al. (2018) · Theranostics · doi:10.7150/thno.24699 · Cited by 29

SAA suppresses α-PD-1 induced anti-tumor immunity by driving TH2 polarization in lung adenocarcinoma

Wang, X., Wen, S., Du, X., Zhang, Y., Yang, X., Zou, R., Feng, B., Fu, X., Jiang, F., Zhou, G., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06198-w · Cited by 28

Metabolic reprograming mediated by tumor cell-intrinsic type I IFN signaling is required for CD47-SIRPα blockade efficacy

Zhou, H., Wang, W., Xu, H., Liang, Y., Ding, J., Lv, M., Ren, B., Peng, H., Fu, Y., & Zhu, M. (2024) · Nature Communications · doi:10.1038/s41467-024-50136-z · Cited by 29

A human commensal-pathogenic fungus suppresses host immunity via targeting TBK1

Luo, G., Zhang, J., Wang, T., Cui, H., Bai, Y., Luo, J., Zhang, J., Zhang, M., Di, L., Yuan, Y., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.07.003 · Cited by 29

Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors

Jirovec, E., Quixabeira, D. C. A., Clubb, J. H. A., Pakola, S. A., Kudling, T. V., Arias, V., Haybout, L., Jalkanen, K., Alanko, T., Monberg, T. J., et al. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-03219-0 · Cited by 28

Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications

Li, W., Yu, C., Zhang, X., Gu, Y., He, X., Xu, R., Xu, J. F., Yu, G., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00300-8 · Cited by 28

Adipose type I interferon signalling protects against metabolic dysfunction

Adolph, T. E., Wieser, V. E., Grander, C., Grabherr, F., Enrich, B., Moser, P. L., Moschen, A. R., Kaser, S., & Tilg, H. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)31656-2 · Cited by 28

A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis

Zhao, Y., Schaafsma, E., Gorlov, I., Hernando, E., Thomas, N. E., Shen, R., Turk, M. J., Berwick, M., Amos, C. I., & Cheng, C. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0173 · Cited by 28

Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer

Merino, V. F., Cho, S., Nguyen, N., Sadik, H., Narayan, A., Talbot, C. C., Cope, L., Zhou, X., Zhang, Z., Győrffy, B., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1068-x · Cited by 28

Infection and cancer suppress pDC derived IFN-I

Greene, T. T., Jo, Y., & Zúñiga, E. I. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.001 · Cited by 28

BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients

Cuevas, E. S., Ouaguia, L., Mouret, S., Charles, J., de Fraipont, F., Manches, O., Valladeau‐Guilemond, J., Bendriss‐Vermare, N., Chaperot, L., & Aspord, C. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1190 · Cited by 32

Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis

Shi, L. Z., & Bonner, J. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212295 · Cited by 28

Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion

Wang, H., Zhang, D., Cui, X., Dai, Y., Wang, C., Feng, W., Lv, X., Li, Y., Wang, L., Ru, Y., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02233-w · Cited by 29

Immune cell–camouflaged surface-engineered nanotherapeutics for cancer management

Jain, N., Shahrukh, S., Famta, P., Shah, S., Vambhurkar, G. B., Khatri, D. K., Singh, S. B., & Srivastava, S. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.11.001 · Cited by 29

IL-6/ERK signaling pathway participates in type I IFN-programmed, unconventional M2-like macrophage polarization

Yang, L., Guo, P., Wang, P., Wang, W., & Liu, J. (2023) · Scientific Reports · doi:10.1038/s41598-022-23721-9 · Cited by 31

Dissecting the role of the gut microbiome and fecal microbiota transplantation in radio- and immunotherapy treatment of colorectal cancer

Dingenen, L. V., Segers, C., Wouters, S., Mysara, M., Leys, N., Kumar‐Singh, S., Malhotra‐Kumar, S., & Houdt, R. V. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1298264 · Cited by 29

6-Hydroxy-3- O -methyl-kaempferol 6- O -glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells

Wonganan, O., He, Y., Shen, X., Wongkrajang, K., Suksamrarn, A., Zhang, G., & Wang, F. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.10.004 · Cited by 28

Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors

Mehla, K., Tremayne, J. R., Grunkemeyer, J. A., O’Connell, K. A., Steele, M. M., Caffrey, T. C., Zhu, X., Yu, F., Singh, P. K., Schultes, B. C., et al. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2095-7 · Cited by 28

The transcription factor NFAT5 limits infection-induced type I interferon responses

Encabo, H. H., Traveset, L., Argilaguet, J. M., Angulo, A., Nistal‐Villán, E., Jaiswal, R., Escalante, C. R., Gekas, C., Meyerhans, A., Aramburu, J. F., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190449 · Cited by 28

Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms

Holmström, M. O., Hasselbalch, H. C., & Andersen, M. H. (2020) · Cancers · doi:10.3390/cancers12071763 · Cited by 28

High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy

Riemann, D., Schütte, W., Turzer, S., Seliger, B., & Möller, M. (2020) · Cancers · doi:10.3390/cancers12102966 · Cited by 28

The emerging era of lactate: A rising star in cellular signaling and its regulatory mechanisms

Wu, D., Zhang, K., Khan, F. A., Wu, Q., Pandupuspitasari, N. S., Tang, Y. Y., Guan, K., Sun, F., & Huang, C. (2023) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30458 · Cited by 28

Engineering Hyaluronic Acid Microneedles Loaded with Mn2+ and Temozolomide for Topical Precision Therapy of Melanoma

Jiang, Y., Jin, Y., Feng, C., Wu, Y., Zhang, W., Xiao, L., Chu, Z., Chen, B., Ma, Y., Qian, H., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303215 · Cited by 27

Single-Dose Physically Cross-Linked Hyaluronic Acid and Lipid Hybrid Nanoparticles Containing Cyclic Guanosine Monophosphate–Adenosine Monophosphate Eliminate Established Tumors

Yu, J., Li, X., Li, J., Sun, N., Peng, C., Huang, J., Li, S., & Kuai, R. (2024) · ACS Nano · doi:10.1021/acsnano.4c10673 · Cited by 27

STING in cancer immunoediting: Modeling tumor-immune dynamics throughout cancer development

Zhang, X., Chen, Y., Liu, X., Li, G., Zhang, S., Zhang, Q., Cui, Z., Qin, M., Simon, H., Terzić, J., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217410 · Cited by 28

Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy

Klepsch, V., Pommermayr, M., Humer, D., Brigo, N., Hermann‐Kleiter, N., & Baier, G. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-019-0454-z · Cited by 27

Hypoxia Regulates Endogenous Double-Stranded RNA Production via Reduced Mitochondrial DNA Transcription

Arnaiz, E., Miar, A., Dias, A. G., Prasad, N., Schulze, U., Waithe, D., Nathan, J. A., Rehwinkel, J., & Harris, A. L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.779739 · Cited by 27

Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma

Najjar, Y. G., McCurry, D., Huang, L., Lin, Y., Zang, Y., Davar, D., Karunamurthy, A. D., Drabick, J. J., Neves, R. I., Butterfield, L. H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4301 · Cited by 28

Role of Hypoxia in the Interferon Response

Arnaiz, E., & Harris, A. L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.821816 · Cited by 28

Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer

Li, M., Xu, J., Jiang, C., Zhang, J., & Sun, T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.842705 · Cited by 27

Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer

Marmonti, E., Oliva, J., & Haymaker, C. (2022) · Cells · doi:10.3390/cells11193028 · Cited by 29

An anti-cancer surveillance by the interplay between interferon-beta and retinoblastoma protein RB1

Qin, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1173467 · Cited by 27

Coupled deglycosylation-ubiquitination cascade in regulating PD-1 degradation by MDM2

Wu, Z., Cao, Z., Yao, H., Yan, X., Xu, W., Zhang, M., Jiao, Z., Zhang, Z., Chen, J., Liu, Y., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112693 · Cited by 27

Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy

Klepsch, V., Hermann‐Kleiter, N., & Baier, G. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.03.007 · Cited by 27

IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion?

Araya, R. E., & Goldszmid, R. S. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.012 · Cited by 27

HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment

Rivero, I. B., García-Vega, Y., Duncan-Roberts, Y., Vazquez-Blomquistc, D., Santana-Milián, H., Besada, V., & Rios-Cabrera, M. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.04.007 · Cited by 27

IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives

Lapenta, C., Gabriele, L., & Santini, S. M. (2020) · Vaccines · doi:10.3390/vaccines8040617 · Cited by 29

Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine

Jia, D., Cai, J., Zhong, Y., Wang, C., Huang, S., Zeng, Y., Fan, Z., Xu, C., Hu, L., Zhang, J., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101229 · Cited by 27

Caspase-9 inhibition triggers Hsp90-based chemotherapy-mediated tumor intrinsic innate sensing and enhances antitumor immunity

Li, J., Han, X., Sun, M., Li, W., Yang, G., Chen, H., Guo, B., Li, J., Li, X., & Wang, H. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007625 · Cited by 27

Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses

Wang, Z., Chen, Y., Wu, H., Wang, M., Mao, L., Guo, X., Zhu, J., Ye, Z., Luo, X., Yang, X., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57997-w · Cited by 28

The EF-Hand Protein CALML6 Suppresses Antiviral Innate Immunity by Impairing IRF3 Dimerization

Wang, Z., Sheng, C., Yao, C., Chen, H., Wang, D., & Chen, S. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.01.030 · Cited by 26

Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer

Plavc, G., Jesenko, T., Oražem, M., & Strojan, P. (2020) · Cancers · doi:10.3390/cancers12113197 · Cited by 27

Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy

Apollonio, B., Ioannou, N., Papazoglou, D., & Ramsay, A. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.626818 · Cited by 27

Co‐occurrence of CDKN2A/B and IFN‐I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma

Peng, Y., Chen, Y., Song, M., Zhang, X., Li, P., Yu, X., Huang, Y., Zhang, N., Ji, L., Xia, L., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13206 · Cited by 26

Emerging role of RNA sensors in tumor microenvironment and immunotherapy

Yang, R. Y., Yu, S., Xu, T., Zhang, J., & Wu, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01261-z · Cited by 27

Chemopreventive and anti-tumor potential of vitamin E in preclinical breast cancer studies: A systematic review

Coêlho, M. D. P. S. D. S., Pereira, I. C., de Oliveira, K. G. F., Oliveira, I. K. F., Rizzo, M. D. S., de Oliveira, V. A., da Silva, F. C. C., Torres‐Leal, F. L., & Sousa, J. M. D. C. E. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2022.11.001 · Cited by 26

Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer

Strauss, B. E., Silva, G. R. O., Vieira, I. D. L., Cerqueira, O. L. D., Valle, P. R. D., Medrano, R. F. V., & Mendonça, S. A. (2018) · Clinics · doi:10.6061/clinics/2018/e479s · Cited by 25

The multiple faces of cGAS-STING in antitumor immunity: prospects and challenges

Zhou, Z., Huang, S., Fan, F., Xu, Y., Moore, C., Li, S., & Han, C. (2024) · Medical Review · doi:10.1515/mr-2023-0061 · Cited by 25

Tumor phagocytosis-driven STING activation invigorates antitumor immunity and reprograms the tumor micro-environment

Lee, S., Hong, K. H., Park, H., Ha, J., Lee, S. E., Park, D. J., Jeong, S. D., Kim, S., Kim, D., Ahn, J., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.004 · Cited by 25

HO-1 impairs the efficacy of radiotherapy by redistributing cGAS and STING in tumors

Zhang, C., Deng, Z., Wu, J., Ding, C., Li, Z., Xu, Z., Chen, W., Yang, K., Wei, H., He, T., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci181044 · Cited by 25

Context-dependent impact of type I interferon signaling in cancer

Ruiz-Iglesias, A., Guilbaud, E., Galluzzi, L., & Mañes, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02495-4 · Cited by 25

Hepatitis E Virus Papain-Like Cysteine Protease Inhibits Type I Interferon Induction by Down-Regulating Melanoma Differentiation-Associated Gene 5

Kim, E., & Myoung, J. (2018) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1809.09028 · Cited by 25

Immunogenic Cell Death Driven by Radiation—Impact on the Tumor Microenvironment

Yamazaki, T., Vanpouille‐Box, C., Demaria, S., & Galluzzi, L. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_10 · Cited by 28

Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis

Hu, Q., Zhou, Q., Xia, X., Shao, L., Wang, M., Lu, X., Liu, S., & Guan, W. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01850-9 · Cited by 25

Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity

Tseng, S.-H., Cheng, M. A., Farmer, E. A., Ferrall, L., Kung, Y. J., Lam, B. K., Lim, L., Wu, T. ‐., & Hung, C. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004342 · Cited by 26

Specialized functions and sexual dimorphism explain the functional diversity of the myeloid populations during glioma progression

Ochocka, N., Segit, P., Wojnicki, K., Cyranowski, S., Swatler, J., Jacek, K., Grajkowska, W., & Kaminska, B. (2023) · Cell Reports · doi:10.1016/j.celrep.2022.111971 · Cited by 28

Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study

Mitsunaga, K., Bagot, M., Ram‐Wolff, C., Guenova, E., von Gugelberg, C., Hodak, E., Amitay‐Laish, I., Papadavid, E., Jonak, C., Porkert, S., et al. (2024) · British Journal of Dermatology · doi:10.1093/bjd/ljae152 · Cited by 27

Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer

Saleh, S. M. I., Bertos, N., Gruosso, T., Gigoux, M., Souleimanova, M., Zhao, H., Ömeroğlu, A., Hallett, M. T., & Park, M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3427 · Cited by 25

A Nanoparticle Platform for Improved Potency, Stability, and Adjuvanticity of Poly(I:C)

Gale, E. C., Roth, G. A., Autzen, A. A. A., Alcántara‐Hernández, M., Idoyaga, J., & Appel, E. A. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900174 · Cited by 25

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

Type I Interferons and Natural Killer Cell Regulation in Cancer

Müller, L., Aigner, P., & Stoiber, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00304 · Cited by 173

The added value of type I interferons to cytotoxic treatments of cancer

Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Musella, M., Manic, G., Maria, R. D., Vitale, I., & Sistigu, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1314424 · Cited by 147